New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
NCT ID NCT07622342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether SHR-2173, added to usual care, improves symptoms of generalized myasthenia gravis (gMG) better than a placebo. About 60 adults with confirmed gMG will receive the drug or placebo for 24 weeks. The main goal is to see if daily muscle weakness and fatigue scores improve.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at debilitating muscle weakness
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New drug trial aims to ease muscle weakness in rare disease
- New shot could ease daily struggles for myasthenia gravis patients
- New study lets myasthenia gravis patients rate their own symptoms on a new drug
- New CAR-T therapy aims to calm overactive immune system in muscle weakness disease